Marvel Biosciences starts work on psychedelics-inspired compounds

The Calgary-based life sciences company hopes to develop treatments for mental health conditions.

Novel molecules may serve as anti-depressants but without inducing hallucinations. metamorworks/Getty Images


Studies have suggested that psychedelics improve what is known as neuroplasticity.

Simply put, neuroplasticity is the brain’s ability to adapt and change.

It’s a process that allows human beings to accomplish a wide range of things, from learning new stuff to coping with mental distress.

In other words, the brain is capable of remarkable feats.

Now, a Calgary-based life sciences company has announced a program to identify and develop “novel, safe agents that promote neuroplasticity”.

Marvel Biosciences Corp. stated in a media release Wednesday (October 27) that these are psychedelics-inspired compounds that come “without the liabilities of abuse potential or hallucinations”.

These risks are often associated with psychedelics, which include ketamine, LSD, DMT, and psilocybin.

In the release, Marvel mentioned that it has “identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing”.

“Although early, this is an auspicious start for our new program that presents a compelling opportunity, as we further expand our product portfolio,” stated Mark Williams, president and chief science officer.

Marvel trades in the TSX Venture Exchange under the ticker symbol MRVL.

As of this post, MRVL shares are trading at $0.28 each.

Follow Carlito Pablo on Twitter at @carlitopablo

Leave your opinion for the editor...We read everything!

Your email address will not be published.